The Board of Pharmacy published its July 2021 Newsletter. Highlights include:
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Industrial Commission of Arizona posted the 2021-22 Fee Schedule Staff Proposals and Request for Public Comment on June 29. The proposal relates to Workers’ Comp claims. The 2021-22 Arizona Physicians’ and Pharmaceutical Fee Schedule includes a new product reimbursement methodology including NADAC. A public hearing will be held on July 29.
Also in Arizona, on July 2, Gov. Doug Ducey (R) announced plans to rescind a variety of pandemic-related executive orders (EOs) related to the public health emergency including these pharmacy-related EOs:
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
On April 9, Gov. Doug Ducey (R) signed into law SB 1356 (Chapter 217, Laws 2021) prohibiting PBMs, from directly or indirectly, holding a pharmacist or pharmacy responsible for a fee related to the claims adjudication process, including adjudicating a pharmacy benefit claim, processing or transmitting a pharmacy benefit claim, developing or managing a claims processing or adjudication network or participating in a claims processing or adjudication network. Pharmacies may file a complaint of a violation, and a PBM that commits a violation is subject to penalties.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Arizona Gov. Doug Ducey (R) has signed into law HB 2075, which delays the implementation of e-prescribing from January 1, 2019 to January 1, 2020. In addition, the bill removes previous law that phased in e-prescribing by county population. The new law enacts e-prescribing for all controlled substances beginning Wednesday, January 1, 2020.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Gov. Doug Ducey (R) signed into law HB 2633 amending the Opioid Law enacted earlier this year during a Special Session. The newly enacted law eliminates the need for pharmacists to verify with the prescriber when a prescription exceeds the state limit for Scheduled II controlled substances containing opioids, eliminates pharmacists having to confirm with the prescriber and the Board of Pharmacy if a prescriber has received a waiver and allows the Board of Pharmacy to waive redcap requirements if it’s not feasible because of specific dosage form or type of packaging.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The House of Representatives passed HB 2633, removing certain requirements included in an opioid omnibus bill, enacted earlier this year. At the federal and state levels alike, NACDS is urging policies that would help address the opioid abuse epidemic, and NACDS also points out the burdens and unintended consequences that some new proposals would create, without helping to address the epidemic. Requirements removed by HB2633 include the following:
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
Gov. Doug Ducey (R) called a special session on January 22 to address the state’s opioid abuse crisis. On January 26, the Governor signed into law SB 1001 that rapidly moved through the legislature. Among the various pharmacy provisions in the bill are requirements for pharmacists to check the prescription drug monitoring program database for all new opioid prescriptions and to place a red cap and adhere a warning label to a prescription vial containing an opioid product. The warning label will be developed via Board of Pharmacy regulations. Beginning January 1, 2019, there will be requirements for e-prescribing of Schedule II controlled substances prescription phased in based upon population in a county with all counties in compliance by July 1, 2019.
Gov. Doug Ducey (R) called for a special session in January to combat the opioid crisis. The Arizona Department of Health Services has developed 12 policy recommendations to address the opioid crisis, including “requiring” e-prescribing, ending dispensing of controlled substances by prescribers, and requiring pharmacists to check the prescription drug monitoring program prior to dispensing.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.